NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) (PA-25-080)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) (PAR-24-293)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed) (RFA-NS-25-018)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) (RFA-NS-25-024)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Application due January 24, 2025. Letter of intent due 30 days prior to application.

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) (PAR-25-051)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

BRAIN Initiative: Optimization of Instrumentation and Device Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed) (RFA-NS-25-017)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Administrative Supplements to Promote Diversity in Research and Development Small Businesses SBIR/STTR (Admin Supp Clinical Trial Not Allowed) (PA-24-255)

Sponsor: National Institutes of Health, Centers for Disease Control and Prevention

Award: Individual(s) must have support under an active grant or cooperative agreement, and the research proposed in the supplement must be accomplished within the competitive segment of the active award. Application budgets are limited to no more than the amount of the current parent award. The project and budget periods must be within the currently approved project period for the existing parent award.

Due Date: Applications are accepted on a rolling basis at any time starting 30 days after the Open Date (varies by IC) until the expiration date (October 14, 2027).

Consortium for Neuroscience AD/ADRD in Low- and Middle-Income Countries (U01 Clinical Trial Not Allowed) (RFA-AG-25-032)

Sponsor: National Institute on Aging

Award: Application budgets are limited to $400,000 in direct cost per year. The project period is limited to 5 years.

Due Date: Letter of Intent due October 7, 2024. Application due November 07, 2024 or February 14, 2025.

NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for AD/ADRD (K99/R00 Clinical Trial Not Allowed) (PAR-24-271)

Sponsor: National Institute on Aging

Due Date: Multiple due dates; see announcement.

Clinical and Translational Science Award (UM1 Clinical Trial Optional) (PAR-24-272)

Sponsor: National Center for Advancing Translational Sciences

Due Date: Multiple due dates; see announcement.

Small Research Grant Program for the Next Generation of Researchers in Low- and Middle-Income Countries for Aging and AD and ADRD Research (R03 Clinical Trial Not Allowed) (RFA-AG-25-031)

Sponsor: National Institute on Aging

Award: Application budgets are limited to $100,000 in direct cost per year. The project period is limited to 2 years.

Due Date: Letter of Intent due October 7, 2024. Application due November 07, 2024 or February 14, 2025.

Notice of Intent to Publish an FOA for NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for AD/ADRD (K99/R00 Clinical Trial Not Allowed)(NOT-AG-24-060)

Sponsor: National Institute on Aging

Due Date: Estimated Publication Date of Notice of Funding Opportunity: November 01, 2024. First Estimated Application Due Date: February 12, 2025.

Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required (RFA-FD-25-001)

Sponsor: U.S. Food and Drug Administration

Due Date: 2024 dates: LOI due September 22, 2024; application due October 22, 2024. 2025 dates: LOI due September 21, 2025; application due October 21, 2025.

McKnight Scholar Awards

Sponsor: The McKnight Endowment Fund for Neuroscience

Award: Applicants for the McKnight Scholar Awards must be independent investigators at not-for-profit research institutions in the United States and must hold a faculty position at the rank of Assistant Professor and must have served at that rank for less than five years at the application deadline. Each Scholar will receive $75,000 annually in 2025, 2026, and 2027. Funds may be used in any way that will facilitate development of the Scholar’s research program, but not for indirect costs.

Due Date: January 13, 2025 at 5 PM Central Time.

Notice of Termination of RFA-NS-24-028: BRAIN Initiative Connectivity across Scales Data Coordinating Center (BRAIN CONNECTS DCC) (U24 Clinical Trial Not Allowed) (NOT-NS-24-127)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: This Notice informs the extramural community that RFA-NS-24-028 “BRAIN Initiative Connectivity across Scales Data Coordinating Center (BRAIN CONNECTS DCC) (U24 Clinical Trial Not Allowed)" will be terminated. The final receipt date, August 21, 2024, has been canceled.